NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.

An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected. Personalised assessments ...

This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We know that AI is vital for the NHS to deliver reduced waiting times and faster diagnoses for patients, which is why the health service plays such a vital role in supporting technologies like DERM by ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

The recommendations in this section are displayed alphabetically by symptom then in order of urgency of the action needed, to make sure that the most urgent actions are not missed. Where there are ...

All NICE products on vulnerable groups. Includes any guidance and quality standards.

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

There is a simple discount patient access scheme for erdafitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...